Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
Wenwei Li1, Yaozong Chen2, Jérémie Prévost3,4, Irfan Ullah5, Maolin Lu1, Shang Yu Gong3,6, Alexandra Tauzin3,4, Romain Gasser3,4, Dani Vézina3,4, Sai Priya Anand3,6, Guillaume Goyette3, Debashree Chaterjee3, Shilei Ding3, William D. Tolbert2, Michael W. Grunst1, Yuxia Bo7, Shijian Zhang8,9, Jonathan Richard3,4, Fei Zhou10, Rick K. Huang10
1Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06520, USA
2Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA
3Centre de Recherche du CHUM (CRCHUM), Montreal, QC H2X 0A9, Canada
4Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
5Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA
6Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada
7Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, K1H 8M5, Canada
8Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
9Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA
10Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA